- Revenue increased 11.1% year-on-year to S$23.1 million
- Driven by maiden revenue contribution from new Mobile and Digital Health Services segment and increase in local sales of Pharmaceutical Services segment
- The Group remained profitable in HY2021 despite the COVID-19 pandemic.